Semaglutide, a medication for Type 2 diabetes and weight management, mimics the hormone GLP-1 to regulate blood sugar and appetite
C., Mi, Z., Kim, S.-H., Ng, B
According to the EMC SmPC, the most commonly reported digestive side effects include: Nausea : Very common (may affect more than 1 in 10 people), typically most pronounced within the first few days after injection and often improving with continued use [1] Vomiting : Common (may affect up to 1 in 10 people), usually associated with eating larger portions than the reduced gastric capacity can comfortably accommodate Abdominal pain and discomfort : Common, resulting from the altered digestive processes Constipation : Common, affecting up to 1 in 10 people due to overall slowing of intestinal transit time Diarrhoea : Common, affecting up to 1 in 10 people, possibly related to altered gut motility patterns Reduced appetite and early satiety : Very common, with patients often feeling uncomfortably full after consuming smaller portions than previously typical These symptoms are generally mild to moderate in severity and tend to diminish as the body adapts to the medication
For India's largely sedentary urban middle class already protein-deficient in many dietary profiles this is a clinically significant concern that startup brochures consistently understate
Which metabolic pathways does Semaglutide target to reduce appetite
We've worked with research teams across hundreds of Ipamorelin protocols
